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Abstract
Introduction Randomized clinical trials have shown that
risedronate and alendronate reduce fractures among women
with osteoporosis. The aim of this observational study was
to observe, in clinical practice, the incidence of hip and
nonvertebral fractures among women in the year following
initiation of once-a-week dosing of either risedronate or
alendronate.
Methods Using records of health service utilization from
July 2002 through September 2004, we created two cohorts:
women (ages 65 and over) receiving risedronate (n=12,215)
or alendronate (n=21,615). Cox proportional hazard model-
ing was used to compare the annual incidence of non-
vertebral fractures and of hip fractures between cohorts,
adjustingforpotentialdifferencesinrisk factorsforfractures.
Results There were 507 nonvertebral fractures and 109 hip
fractures. Through one year of therapy, the incidence of
nonvertebral fractures in the risedronate cohort (2.0%) was
18% lower (95% CI 2% – 32%) than in the alendronate
cohort (2.3%). The incidence of hip fractures in the
risedronate cohort (0.4%) was 43% lower (95% CI 13% –
63%) than in the alendronate cohort (0.6%). These results
were consistent across a number of sensitivity analyses.
Conclusion Patients receiving risedronate have lower rates
of hip and nonvertebral fractures during their first year of




Osteoporosis, a common skeletal disease in older popula-
tions, leads to more than a million fractures annually in the
United States [1]. Nonvertebral fractures represent 75% of
osteoporotic fractures seen in clinical practice [2]. The
incidence of nonvertebral fractures, especially at the hip,
increases rapidly with age [3]. In order to prevent these
fractures, US clinical guidelines recommend that candidates
for osteoporosis therapy be identified by screening the bone
mineral density of all woman ages 65 and over (age 60 for
high risk populations) [4].
Oral bisphosphonates are currently the most common
therapy for osteoporosis [5]. While the three most utilized
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approved by the Food and Drug Administration have been
shown to reduce vertebral fractures in randomized clinical
trials, it is unknown if these three are equally effective in
reducing nonvertebral fractures of real-world patients in
clinical practice. A comparison of the results from the
randomized clinical trials of each bisphosphonate, though
limited by methodological differences between trials,
suggests potential differences in degree of fracture reduc-
tion across bisphosphonates. In the primary analyses of the
trials that followed patients for at least 3 years, risedronate
significantly reduced the incidence of nonvertebral fractures
by up to 39% [6, 7]; alendronate reduced the incidence of
nonvertebral fractures by up to 21% [8–10]; ibandronate
did not reduce nonvertebral fractures [11]. Post-hoc
analyses of these trial data suggest that there are differences
in the onset of fracture reduction. In those analyses,
reduction of nonvertebral fractures began at 6 months for
5m gd a i l yd o s i n go fr i s e d r o n a t e[ 12] and at either
12 months (when fractures were recorded as adverse
events) for 10 mg daily dosing of alendronate [13]o r
24 months for 5 mg daily dosing of alendronate [14]. These
possible differences in both the amount and the onset of
fracture reduction between the bisphosphonates could arise
from their differences in structure, potency, and binding
properties [15].
The only direct comparison of bisphosphonates in a
randomized clinical trial is based on surrogate endpoints
(e.g., changes in bone mineral density and markers of
bone turnover) [16]. However, the association between
changes in these surrogates and subsequent fracture
reduction is not consistent across studies [17, 18]. Unlike
randomized clinical trials based on surrogate endpoints,
observational studies of large populations provide the
opportunity to use major disease endpoints (e.g., hip
fracture) as the outcome of interest. The limitation of
observational studies can be misleading results from bias
arising from non-randomized treatment groups. This bias
can be accounted for in part by statistically adjusting for
known risk differences between groups. Furthermore,
when different therapies are available to be prescribed
for the same indication, there is at least some expectation
of similarity in prognostic factors between treatment
groups occurring naturally [19]. For example, observa-
tional studies have compared both the many antihyper-
tensive drug therapies and many statins for reducing the
disease endpoint of myocardial infarctions [20, 21].
Since the once-a-week dosing regimens of both risedron-
ate and alendronate have been available in the US since
2002, there is now an opportunity to observe their effect on
reducing fractures in a large population of patients seen in
clinical practice. Hence, we conducted an observational
study across multiple US health plans to observe the
incidence of hip and nonvertebral fractures among women
ages 65 and over following initiation of therapy with once-
a-week dosing of either risedronate or alendronate.
Methods
The RisedronatE and ALendronate (REAL) cohort study
was a retrospective observation of bisphosphonate
patients within healthcare utilization records in the United
States. The analysis plan was based upon an earlier report
[22]. All authors had access to the data. For assurance of
reproducibility [23], the analyses were independently
replicated by the respective organizations of the authors.
The reporting of this study is consistent with the STROBE
guidelines [24].
Data source
The data source was commercially available datasets of
healthcare utilization from the 1 health plan within Ingenix
Lab/Rx (Eden Prairie, MN; data through June 2004) and
the 100 health plans of employers within MedStat Market-
scan (Ann Arbor, MI; data through September 2004). These
datasets contain a longitudinal history of patient-specific
data including demographic information (sex, age, dates of
dataset inclusion), clinical encounters (inpatient and outpa-
tient services by associated procedures and diagnoses
specified by the International Classification of Diseases,
Ninth Revision, Clinical Modification (ICD-9-CM)), and
outpatient pharmaceutical dispensations (retail and mail
order specified by the national drug code (NDC)). To
maximize sample size, the two datasets were combined for
all analyses. At the time of data extraction for the current
study, the combined datasets contained 12 million persons
across 34 states in the US.
Study population
Within the data source, candidates for study inclusion were
all women aged 65 and older with any use of once-a-week
dosing of risedronate (35 mg; Actonel, P&G Pharmaceuti-
cals) or once-a-week dosing of alendronate (35 or 70 mg;
Fosamax, MSD) after July 2002, a date corresponding with
contemporaneous commercial availability of once-a-week
versions of both therapies (Fig. 1). Patient exclusion criteria
and rationale were: 1) less than 6 months (182 days) of
health plan enrollment before their first bisphosphonate use
after July 2002, a history period to measure baseline
fracture risk; 2) less than 3 months (92 days) of health
plan enrollment after their first bisphosphonate use, a
minimum observation period with expectation of any
fracture reduction (based on post-hoc analyses of clinical
26 Osteoporos Int (2007) 18:25–34trials [12, 14]); 3) any bisphosphonate use (daily, weekly, or
Paget's doses) during their 6 month history period, to include
only patients who are new users of bisphosphonates; 4)
diagnosis of malignant neoplasm, ICD-9-CM 140 - 208; or
Paget's disease, ICD-9-CM 731.0 during either the 6 month
history period or first 3 months of observation, to exclude
patients with fracture risk not related to osteoporosis; and 5)
discontinued therapy within the first 3 months, a minimum
period of therapy adherence.
Length of observation
Observation for a subject was censored at one of following
end points, whichever occurred first: date of fracture,
12 months after date of first bisphosphonate prescription,
end date of health plan enrollment, date of switch between
bisphosphonate therapies or end date of therapy adherence.
Adherence was measured as a function of the gaps between
refills, which provides the best available measure within
datasets of medical claims [25]. Once the gap between the
completion of a 30-day supply and the start of a new
prescription exceeded 15 days, the end date of therapy
adherence was the prescription date before gap plus 45 days.
For a 90-day supply, a gap of 45 days was allowed between
completion and a new prescription, the end date of therapy
adherence was the prescription date before gap plus
135 days. For the last prescription, the end date of therapy
adherence was the date of last prescription plus 45 days for
a 30-day supply and date of last prescription plus 135 days
for a 90-day supply.
Fig. 1 Identification of the
study population
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From the data source, two outcomes were identified:
subjects with nonvertebral fractures collectively (hip, wrist,
humerus, clavicle, pelvis, leg - sites previously specified
[12]) and subjects with a hip fracture. Vertebral fractures
were not included because the majority of them do not
come to clinical attention and thus not systematically
captured in the data source. In an attempt to identify
incident fractures more likely related to osteoporosis, we
used a series of exclusion criteria (Table 1). A total of 109
hip and 507 nonvertebral fracture patients were available
for analyses.
Statistical analyses
To assess the comparability of baseline characteristics (see
Table 2 for specific definitions of demographic character-
istics and health history) between the risedronate and
alendronate cohorts, the chi-square test was used for
dichotomous variables and the Wilcoxon rank sum test
was used for continuous variables.
For the primary analysis, the main outcome measures
were the 6 and 12 month incidence of nonvertebral
fractures and hip fractures. Cox proportional hazard
modeling (PROC PHREG, SAS Institute, Cary, NC) was
used to compare the incidence of fractures between
risedronate and alendronate cohorts, adjusting for potential
differences in measurable risk factors for fractures. A
parsimonious model for each outcome was developed to
enhance precision of the parameter estimates and interpre-
tation of results. The selection of variables to be included in
the model was based on forward selection. These models
were checked against models based on backward selection.
The appropriateness of the proportional hazard assumption
was assessed by graphical and numerical methods (AS-
SESS statement, SAS Institute).
In order to evaluate if the results of the primary analysis
were dependent on methodology, sensitivity analysis were
used to compare the incidence of fractures between
risedronate and alendronate cohorts. These methods includ-
ed: (1) an intent-to-treat analysis that observed all subjects
for 12 months regardless of therapy adherence; (2) a
proportional hazard model using the propensity score to
adjust for differences in baseline fracture risk between
cohorts; (3) use of different inclusion criteria for the study
population; (4) use of different inclusion criteria for the
study outcomes (see Fig. 5 for specifics).
Results
The risedronate cohort included 12,215 subjects on once-a-
week dosing of 35 mg followed for a mean of 226 days on
therapy. 37% of this cohort was censored before 12 months
because of the end date of available data and 41% was
censored for an end in therapy adherence. The alendronate
cohort included 21,615 subjects on once-a-week dosing of
35 mg (8%) or 70 mg (92%) followed for a mean of
238 days on therapy. 33% of this cohort was censored
before 12 months because of the end date of available data
and 41% was censored for an end in therapy adherence.
Upon start of bisphosphonate therapy, the two cohorts were
different in several baseline characteristics (Table 2).
Statistically, the risedronate cohort was older, had more
concomitant medications, had more use of glucocorticoids,







Subjects with a medical claim for fracture during the observation period after initial bisphosphonate. 135 923
Exclusion of medical claim if a fracture at the same site both before and after start of bisphosphonate therapy;
in order to increase the likelihood of including only new fractures.
−16 −368
Exclusion of medical claim if a fracture at an unspecified site
c before the start of bisphosphonate therapy;
in order to increase the likelihood of including only new fractures.
−2 −6
Exclusion of medical claim if an open fracture
d; in order to decrease the likelihood of including traumatic
fractures.
−3 −11
Exclusion of medical claim if documented cause (E-codes) of injury is other than an accidental fall
e;
in order to decrease the likelihood of including traumatic fractures.
−5 −31
Subjects with a fracture outcome 109 507
aInpatient ICD-9-CM codes (820.x, 733.14)
bIn addition to inpatient hip fractures, inpatient and outpatient ICD-9-CM codes for fracture of the wrist (813.x, 733.12), humerus
(812.x, 733.11), clavicle (810.x), pelvis (808.x), and leg (821.x, 823.x, 733.15, 733.16)
cICD-9-CM code (733.10 or 733.19)
dICD-9-CM code that is not 733.1x or where the 4th digit is not=.1, .3, .5, .9
eICD-9-CM code with “E” classification (E880 - E888) for accidental falls
28 Osteoporos Int (2007) 18:25–34and had more patients with rheumatoid arthritis than the
alendronate cohort - characteristics that may increase
fracture risk. Conversely, the risedronate cohort also had
greater past use of calcitonin or raloxifene - a character-
istic that may decrease fracture risk. Within the 12 months
prior to the initiation of bisphosphonate therapy, similar
percentages of the two cohorts had a diagnosis for a
nonvertebral fracture and a clinical vertebral fracture,
while a statistically larger percentage of the risedronate
cohort had a diagnosis for a hip fracture than the
alendronate cohort (Fig. 2).
During the 12 months of observation after the start of
bisphosphonate therapy, 507 subjects had nonvertebral
fractures. The site of nonvertebral fracture was wrist
(30%), hip (21%), leg (17%), pelvis (15%), humerus
(14%), and clavicle (3%). For the 109 women hospitalized
with a hip fracture, the skeletal sites were intertrochanteric
(46%), transcervical (28%), unspecified (20%), and tro-
chanteric or subtrochanteric (6%).
For the primary analysis of nonvertebral fractures, the
fracture incidence was similar between the risedronate and
alendronate cohorts over the first 3 months of therapy
(Fig. 3). After 6 months of therapy, the risedronate cohort
had a 19% lower (95% CI 0% – 35%, p-value=0.05)
incidence of nonvertebral fracture than the alendronate
cohort. After 12 months of therapy, the risedronate cohort
had an 18% lower (95% CI 2% – 32%, p-value=0.03)
incidence of nonvertebral fracture than the alendronate
cohort (Table 3).
For the primary analysis of hip fractures, the fracture
incidence was similar between the risedronate and alendron-
ate cohorts over the first 3 months of therapy (Fig. 4). After
6 months of therapy, the risedronate cohort had a 46%
l o w e r( 9 5 %C I9 %– 68%, p-value=0.02) incidence of
Table 2 Comparison of baseline characteristics between cohorts in study
Cohorts
Characteristic Risedronate Alendronate p-value
Number of women subjects 12,215 21,615
Duration of observation period
Days (mean) 226 238 < 0.001
Age at study entry
Years & months (mean) 74 & 10 74 & 7 < 0.001
Ages 65 – 74 (%) 53.5 52.4
Ages 75 – 84 (%) 36.8 36.7
Ages 85 and over (%) 9.7 11.0
Medications – 6 month history
a
Concomitant medications (mean)
b 4.0 3.6 < 0.001
Gastrointestinal medication use (%)
c 26.2 20.1 < 0.001
Estrogen use (%)
d 17.2 16.5 0.08
Other non-estrogen anti-osteoporotic use (%)
e 15.6 11.0 < 0.001
Glucocorticosteroid use (%)
f 10.3 8.5 < 0.001
Medical encounters – 6 month history
a
Office visits (mean) 5.6 5.1 < 0.001
Hospitalization (%) 8.2 8.2 0.87
Osteoporosis diagnosis (%)
g 37.7 33.8 < 0.001
Osteopenia diagnosis (%)
h 12.5 10.5 < 0.001
Bone densitometry procedure (%)
i 47.4 41.5 < 0.001
Gastrointestinal diagnosis (%)
j 15.4 12.3 < 0.001
Rheumatoid arthritis diagnosis (%)
k 2.7 2.3 0.01
aSix months before and including date of starting first bisphosphonate prescription
bBased on number of therapeutic classes with a prescription [34]
cBased on NDC codes for at least one prescription for either: H2 antagonists (ranitidine, cimetidine, famotidine, nizatidine); Proton pump
inhibitors (omeprazole, esomeprazole, lansoprazole, pantoprazole); Cytoprotectives (misoprostol, sucralfate) [35]
dBased on NDC codes for at least one prescription of estradiol, conjugated estrogen, esterified estrogen, or estropipate
eBased on NDC codes for at least one prescription of calcitonin or raloxifene
f Based on NDC codes for at least one prescription for triamcinolone, prednisone, prednisolone, methylprednisolone, dexamethasone, budesonide,
betamethasone, cortisone, or hydrocortisone
gICD-9 733.0x
hICD-9 733.90 and no record of 733.0x
iCPT 76070, 76075, 76076, 78350, 78351, ICD-9 88.98
jMultiple ICD-9 codes [36]
kICD-9 714.0
Osteoporos Int (2007) 18:25–34 29hip fracture than the alendronate cohort. After 12 months
of therapy, the risedronate cohort had a 43% lower (95%
CI 13% – 63%, p-value=0.01) incidence of hip fracture
than the alendronate cohort (Table 3).
These differences between the risedronate and alendron-
ate cohorts in the incidence of fractures were consistent
across other methods of analysis (Fig. 5). Depending on the
method, the risedronate cohort had an estimated 6% to 23%
lower incidence of nonvertebral fractures and an estimated
30% to 50% lower incidence of hip fractures than the
alendronate cohort through 12 months of therapy. All of
these other estimates were within the confidence intervals
of the primary analyses.
Patients at risk (fracture events)
Alendronate 21615 (0) 21489 (126) 12794 (253) 8439 (308) 5319 (343)
Risedronate 12215 (0) 12147 (68) 6743 (123) 4196 (152) 2449 (164)

















































Fig. 3 Cumulative incidence of
nonvertebral fractures in patients
treated with alendronate or
risedronate for up to 1 year
Fig. 2 Percent of patients with
a clinical diagnosis of fracture
before initiation of bisphospho-
nate therapy.
1ICD-9 codes
808.x, 810.x, 812.x, 813.x,







(81%) of study population with
available 12 month history.
*Statistical difference (p<0.05)
between cohorts
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In this observational study across multiple US health plans,
we observed that patients on once-a-week dosing of
risedronate had a lower incidence of hip and nonvertebral
fractures than patients on once-a-week dosing of alendron-
ate. Differences in fracture incidence between these two
cohorts of patients were observed at 6 and 12 months after
initiating therapy.
As with all observational studies, systematic errors (e.g.,
selection bias, measurement misclassification) may be the
basis for the observed results [26]. In this study, systematic









b Adjusted rate ratio





Alendronate 21,615 253 1.31 –– – –
Risedronate 12,215 123 1.14 0.87 0.81 0.65–1.00 0.05
12 Months
Alendronate 21,615 343 2.30 –– – –
Risedronate 12,215 164 1.99 0.88 0.82 0.68–0.98 0.03
Hip
6 Months
Alendronate 21,615 54 0.29 –– – –
Risedronate 12,215 19 0.17 0.63 0.54 0.32–0.91 0.02
12 Months
Alendronate 21,615 80 0.58 –– – –
Risedronate 12,215 29 0.37 0.68 0.57 0.37–0.87 0.01
CI=confidence interval of adjusted rate ratio
aProportion is based on Kaplan-Meier estimate of the survival function.
bBased on Cox regression model.
cBased on Cox regression model. Variables selected by forward stepwise selection where criteria for selection p<0.1. Model for nonvertebral
fractures included age, estrogen use, number of medications, rheumatoid arthritis diagnosis, and history of nonvertebral fractures. Model for hip
fractures included age, estrogen use, number of medications, and history of hospitalization.








































Patients at risk (fracture events)
Alendronate 21615 (0) 21590 (25) 12993 (54) 8677 (69) 5582 (80)
Risedronate 12215 (0) 12202 (13) 6847 (19) 4319 (27) 2584 (29)
Fig. 4 Cumulative incidence of
hip fractures in patients treated
with alendronate or risedronate
for up to 1 year
Osteoporos Int (2007) 18:25–34 31errors may arise from differences in fracture risk between
the 2 cohorts of patients at initiation of therapy. Between
the two cohorts, there were statistical differences in
measurable fracture risk characteristics (Table 2), there are
likely to be differences in known fracture risk character-
istics not available within medical claims data (e.g., bone
mineral density, family history, smoking history), and there
are likely to be differences in unknown fracture risk
characteristics (i.e., those that are controlled through
randomized trials). The differences in measurable fracture
risk characteristics, for which a greater percentage of the
risedronate cohort has risk factors for fracture than the
alendronate cohort suggesting bias towards higher fracture
rates in the risedronate cohort, are inconsistent with
observed results. The near unity in fracture incidence
between the two cohorts during the first 3 months of
therapy (Figs. 3 and 4) - a period for which there is also
unity in fracture incidence between bisphosphonate therapy
and placebo in clinical trials [12, 14] - suggest that both
cohorts had similar risk for fracture at initiation of therapy.
However, differences in fracture risk at initiation of therapy



















































































































































































Symbol legend for method of
analysis
. Primary analysis (n = 33,830) that
followed subjects during their
therapy, where the number of study
outcomes was n = 109 hip fractures
and n = 507 nonvertebral fractures;
proportional hazard modeling to
adjust for differences in baseline
characteristics of fracture risk
Intent-to-treat analysis
1) Intent to treat analysis (n = 33,830 +
17,329) that included all subjects
with at least 1 prescription and no
censoring for an end in therapy
adherence
Propensity analysis
2) Propensity analysis (n = 33,830) for
statistical adjustment of differences
in baseline fracture risk
Change in inclusion criteria for the study
population
3) Excluded subjects (n = 33,830 - 3,086)
with historical use of steroids
4) Excluded subjects (n = 33,830 -
9,505) with historical use of
estrogen, calcitonin, or raloxifene
5) Added subjects (n = 33,830 + 43,032)
having a history period of less than 6
months
6) Excluded subjects (n = 33,830 - 1,768)
using alendronate 35 mg
7) Excluded subjects (n = 33,830 –
2,235) with a clinical diagnosis of hip,
nonvertebral, or vertebral fracture 
 
bisphosphonate therapy
during the 6 month period before 
Change in inclusion criteria for the study
outcome
8) Analysis (n = 33,830) with no
exclusion of any medical claims for a
fracture, hence the number of
outcomes was n = 135 hip fractures
and n = 923 nonvertebral fractures
Fig. 5 Sensitivity analysis: Rate
ratio for fracture in the first year
of therapy between patients on
risedronate and patients on
alendronate; results of the pri-
mary analysis and 4 other
methods of analyses
32 Osteoporos Int (2007) 18:25–34Within healthcare utilization data, which are collected
for purposes other than research, misclassification of
fracture events and of therapy use are inevitable. As a
check on the data, the rate of fracture events and therapy
use of these health utilization data are in agreement with
other data sources. In the current study, the annual fracture
rates following initiation of therapy (≈2.0% for nonverte-
bral fractures and ≈0.5% for hip fractures) are consistent
with the annual rates in the treated population of clinical
trials (between 2.0 and 2.3% for nonvertebral fractures and
between 0.4% and 0.7% for hip fractures [6–10, 27]). In
this study, risedronate patients constituted 25% [45,360/
(45,360+137,412)] of the bisphosphonate users in the
utilization data compared to 24% [13.6 million / (13.6
million+44.1 million)] of all bisphosphonate prescriptions
in the US during the same period [28]. A good method for
evaluating misclassification within healthcare utilization
data is through a medical chart review. In a prior study,
the proportion of fracture claims confirmed by chart review
to be a fracture was highest for the hip relative to other
fracture sites [29]. Since the effect of misclassification at
these other fracture sites is likely to be no different between
cohorts (i.e., misclassified exposure does not depend on
cohort status), the study results for nonvertebral outcomes
are likely more attenuated by misclassification than results
for the hip [30].
The strength of observational studies can be the
generalizability of results. In contrast, the generalizability
of results from randomized trials to a real world setting can
be limited by differences between the two in relation to
expertise of health care provider, quality of medical care,
course of therapy, and types of patients [31]. For example,
it has been observed that the majority of patients considered
candidates for osteoporosis therapy by their physician
would not meet the eligibility criteria for inclusion in the
randomized trials [32]. Since the population within the
current observational study is drawn from multiple health
plans in many US states and consists of subjects with a
mixture of health characteristics (e.g., prior gastrointestinal
comorbidities), the results are likely to be generalizable.
Furthermore, the length of observation of therapy adher-
ence (≈232 days) in the current study was consistent to the
previously reported average duration of adherence to
bisphosphonate therapy (245 days) [33].
In conclusion, within this observational study of clinical
practice, a cohort of patients receiving risedronate had
lower rates of hip and nonvertebral fractures during their
first year of therapy than a cohort of patients receiving
alendronate. These results do not appear to be explained by
baseline differences in fracture risk between cohorts. In
addition, the observed rates of fracture were consistent with
the fracture rates in clinical trials. Thus it appears, patients
receiving risedronate are better protected from hip and
nonvertebral fractures during their first year of therapy than
patients receiving alendronate.
Financial Disclosures Drs. Silverman, Watts, Delmas, and Lindsay
have received consulting fees, lecture fees, or research grants from
The Alliance for Better Bone Health (Procter & Gamble Pharmaceuti-
cals and sanofi-aventis). Dr. Lange is an employee of Procter &
Gamble Pharmaceuticals.
Support The data source for this article was leased by The Alliance
for Better Bone Health. Every author had full access to all of the data
and takes responsibility for the integrity of the data and the accuracy
of the data analysis.
References
1. U.S. Department of Health and Human Services (2004) Bone
Health and Osteoporosis: A Report of the Surgeon General. U.S.
Department of Health and Human Services, Office of the Surgeon
General, Rockville, MD
2. Tosteson A, Solomon D, King AB, Dawson-Hughes B, Burge R,
Wong J (2005) Projections of osteoporosis fractures and costs by
skeletal sites in the USA. ASBMR 27th annual meeting, Nashville, TN
3. Melton LJ 3rd, Crowson CS, O'Fallon WM (1999) Fracture
incidence in Olmsted County, Minnesota: comparison of urban
with rural rates and changes in urban rates over time. Osteoporos
Int 9:29–37
4. U.S. Preventive Services Task Force (2002) Screening for Osteoporosis
in Postmenopausal Women: Recommendations and Rationale.
Agency for Healthcare Research and Quality, Rockville, MD
5. Stafford RS, Drieling RL, Hersh AL (2004) National trends in
osteoporosis visits and osteoporosis treatment, 1988–2003. Arch
Intern Med 164:1525–1530
6. Harris ST, Watts NB, Genant HK et al (1999) Effects of
risedronate treatment on vertebral and nonvertebral fractures in
women with postmenopausal osteoporosis: a randomized con-
trolled trial. Vertebral Efficacy With Risedronate Therapy (VERT)
Study Group. JAMA 282:1344–1352
7. ReginsterJ,MinneHW,SorensenOHetal(2000).Randomizedtrialof
the effects of risedronate on vertebral fractures in women with
established postmenopausal osteoporosis. Vertebral Efficacy with
Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83–91
8. Liberman UA, Weiss SR, Broll J et al (1995) Effect of oral
alendronate on bone mineral density and the incidence of fractures
in postmenopausal osteoporosis. The Alendronate Phase III Osteo-
porosis Treatment Study Group. N Engl J Med 333:1437–1443
9. Black DM, Cummings SR, Karpf DB et al (1996) Randomised
trial of effect of alendronate on risk of fracture in women with
existing vertebral fractures. Fracture Intervention Trial Research
Group. Lancet 348:1535–1541
10. Cummings SR, Black DM Thompson DE et al (1998) Effect of
alendronate on risk of fracture in women with low bone density
but without vertebral fractures: results from the Fracture Inter-
vention Trial. JAMA 280:2077–2082
11. Chesnut III CH, Skag A, Christiansen C et al (2004) Effects of oral
ibandronate administered daily or intermittently on fracture risk in
postmenopausal osteoporosis. J Bone Miner Res 19:1241–1249
12. Harrington JT, Ste-Marie LG Brandi ML et al (2004) Rise-
dronate rapidly reduces the risk for nonvertebral fractures in
women with postmenopausal osteoporosis. Calcif Tissue Int
74:129–135
13. Pols HA, Felsenberg D, Hanley DA et al (1999) Multinational,
placebo-controlled, randomized trial of the effects of alendronate
Osteoporos Int (2007) 18:25–34 33on bone density and fracture risk in postmenopausal women with
low bone mass: results of the FOSIT study. Foxamax International
Trial Study Group. Osteoporos Int 9:461–468
14. Black DM, Thompson DE, Bauer DC et al (2000) Fracture risk
reduction with alendronate in women with osteoporosis: the
Fracture Intervention Trial. J Clin Endocrinol Metab 85:4118–4124
15. Nancollas GH, Tang R, Phipps RJ, et al (2006) Novel insights into
actions of bisphosphonates on bone: differences in interactions
with hydroxyapatite. Bone 38:617–627
16. Rosen CJ, Hochberg MC, Bonnick SL et al; Fosamax Actonel
Comparison Trial Investigators (2005) Treatment with once-
weekly alendronate 70 mg compared with once-weekly risedron-
ate 35 mg in women with postmenopausal osteoporosis: a
randomized double-blind study. J Bone Miner Res 20:141–151
17. Watts NB, Geusens P, Barton IP, Felsenberg D (2005) Relation-
ship between changes in BMD and nonvertebral fracture
incidence associated with risedronate: reduction in risk of non-
vertebral fracture is not related to change in BMD. J Bone Miner
Res 20:2097–2104
18. HochbergMC,GreenspanS,WasnichRD,MillerP,ThompsonDE,
Ross PD (2002) Changes in bone density and turnover explain the
reductions in incidence of nonvertebral fractures that occur during
treatment with antiresorptive agents. J Clin Endocrinol Metab
87:1586–1592
19. Klungel OH, Martens EP, Psaty BM et al (1995) Methods to
assess intended effects of drug treatment in observational studies
are reviewed. J Clin Epidemiol 57:1223–1231
20. Psaty BM, Heckbert SR, Koepsell TD et al (1995) The risk of
myocardial infarction associated with antihypertensive drug
therapies. JAMA 274:620–625
21. Zhou Z, Rahme E, Abrahamowicz M et al (2005) Effectiveness of
statins for secondary prevention in elderly patients after acute
myocardial infarction: an evaluation of class effect. CMAJ
172:1187–1194
22. Watts NB, Worley K, Solis A, Doyle J, Sheer R (2004) Comparison
of risedronate to alendronate and calcitonin for early reduction of
nonvertebral fracture risk: results from a managed care adminis-
trative claims database. J Manag Care Pharm 10:142–151
23. Peng RD, Dominici F, Zeger SL (2006) Reproducible epidemio-
logic research. Am J Epidemiol 163:783–789
24. Strengthening the reporting of observational studies in epidemi-
ology (STROBE). Available at http://www.strobe-statement.org.
Accessed 14 June 2006
25. Sikka R, Xia F, Aubert RE (2005) Estimating medication
persistency using administrative claims data. Am J Manag Care
11:449–457
26. Grimes DA, Schulz KF (2002) Bias and causal associations in
observational research. Lancet 359:248–252
27. McClung MR, Geusens P, Miller PD et al (2001) Effect of
risedronate on the risk of hip fracture in elderly women. Hip
Intervention Program Study Group. N Engl J Med 344:333–
340
28. IMS Health, National Prescription Audit Plus, Plymouth Meeting,
PA
29. Ray WA, Griffin MR, Fought RL, Adams ML (1992) Identifica-
tion of fractures from computerized Medicare files. J Clin
Epidemiol 45:703–714
30. Kelsey JL, Thompson WD, Evans AS (1986) Methods in
Observational Epidemiology. Oxford University Press, Oxford
31. Black N (1996) Why we need observational studies to evaluate
the effectiveness of health care. BMJ 312:1215–1218
32. Dowd R, Recker RR, Heaney RP (2000) Study subjects and
ordinary patients. Osteoporos Int 11:533–536
33. McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J (2004)
Compliance with drug therapies for the treatment and prevention
of osteoporosis. Maturitas 48:271–287
34. McEvoy GK (ed) (2005) AHFS Drug Information 2005. Amer-
ican Society of Health-System Pharmacists, Bethesda, MD
35. Kane S, Borisov NN, Brixner D (2004) Pharmacoeconomic
evaluation of gastrointestinal tract events during treatment with
risedronate and alendronate: a retrospective cohort study. Am J
Manag Care 10:S216–S226
36. Miller RG, Bolognese M, Worley K, Solis A, Sheer R (2004)
Incidence of gastrointestinal events among bisphosphonate sub-
jects in an observational setting. Am J Manag Care 10:S207–
S215
34 Osteoporos Int (2007) 18:25–34